PFAS Exposure Could Make COVID-19 Vaccine Less Effective: Study

Research suggests the effectiveness of COVID-19 vaccines may be impacted by exposure to toxic chemicals found in some firefighter foams and other products, which have caused widespread water contamination in many communities throughout the U.S. in recent years.

In a recent report, Danish researchers indicate they discovered at least five per- and polyfluoroalkyl substances (PFAS) compounds, known to be immunotoxic, which appear to increase the severity of COVID-19 infections, and may undermine the effectiveness of the new vaccines designed to fight the pandemic. The findings have not yet been peer reviewed and are considered preliminary, but may raise concerns in certain communities.

Aqueous film-forming foam (AFFF)ย has been widely used for decades to fight petroleum-based fires, which cannot be controlled or subdued by water alone. However, many versions of the fire foam contained PFAS chemicals, which are commonly referred to as โ€œforever chemicalsโ€ because they can take decades to break down. They can also build up in the water, soil or human body, increasing the risk of cancer and other injuries.

AFFF Cancer Lawsuit
AFFF Cancer Lawsuit

In the United States, a number of communities around military bases, airports and other firefighter training locations have been found to contain high levels of PFAS in local water sources, which are often difficult to remove.

In this latest study, researchers took plasma samples from 323 subjects between the ages of 30 and 70 with known COVID-19 infections, and measured them for five PFAS chemicals known to be immunotoxic.

The researchers found plasma PFAS levels were higher in males, those with Western European backgrounds, and those levels increased with age. In addition, the presence of one particular PFAS compound, known as perfluorobutanoic acid (PFBA) more than doubled the risk of a severe infection. Once they accounted for age, sex, and other factors, that lowered to nearly an 80% increased risk.

โ€œElevated plasma-PFBA concentrations were associated with an increased risk of more severe course of COVID-19,โ€ the researchers concluded. โ€œGiven the low background exposure levels in this study, the role of PFAS exposure in COVID-19 needs to be ascertained in populations with elevated exposures.โ€

Their early findings, first reported in October, did not garner much attention. However, now experts are warning the increased severity caused by some PFAS compounds could counteract the benefits of the vaccines, which greatly decrease the severity of COVID-19 infections, in addition to preventing infections.

โ€œThere is evidence from human and animal studies that PFAS exposure may reduce antibody responses to vaccines and may reduce infections disease resistance,โ€ the U.S. Centers for Disease Control and Prevention warned in a statement. โ€œBecause COVID-19 is a new public health concern, there is still much we donโ€™t know. More research is needed to understand how PFAS exposure may affect illness from COVID-19.โ€

In recent months, much of the focus on PFAS chemical exposure has been linked to the use of firefighting foams. Chemical and safety equipment manufacturers face hundreds of firefighting foam lawsuitsย pending nationwide, including claims presented by local governments and water districts, as well as claims brought by former firefighters diagnosed with testicular cancer, kidney cancer, pancreatic cancer and other injuries after direct exposure to the chemicals.

Given common questions of fact and law raised in the PFAS litigation, all cases filed throughout the federal court system are currently centralized in the U.S. District Court for the District of South Carolina for coordinated discovery and pretrial proceedings, where small groups of water contamination cases and cancer claims are being prepared for early trial dates.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.




0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Plaintiffs and defendants involved in hair relaxer cancer lawsuits are expected to turn in a list of 12 cases that the parties believe are fit to serve as bellwether trials.
Cartiva implant lawsuits are moving forward in federal court as patients across the United States seek compensation for complications linked to the recalled big toe device.
An Abbott spinal cord stimulator lawsuit filed by three women says the product was defectively designed, inappropriately approved by the FDA, and left them with severe injuries, worsening pain and the need for removal surgery.